The Spark is a Lantern Pharma newsletter that provides succinct and frequent updates about Lantern, our RADR® AI and ML platform, and our pipeline of drug programs. Subscribe to the newsletter to receive it by email or see the most recent editions below.
The May 2023 edition of The Spark features the latest Lantern updates including:
In early May, Lantern submitted the LP-184 investigationalnew drug (IND) application to the US FDA. The IND submission isa major regulatory milestone for LP-184 and supports its advancementtoward a first-in-human Phase 1 clinical trial, which is targeted to launchin Q2 2023.
What's next: The upcoming LP-184 Phase 1A basket trial is expected toenroll 30-35 patients with solid tumors and central nervous system(CNS) cancers including:
Go deeper: Insights from Lantern’s AI Platform, RADR®, rapidlyaccelerated the development of LP-184 towards the clinic and aided indiscovering LP-184’s mechanism of action, identifying and prioritizing itscancer indications, and generating machine-learning biomarkersignatures to assist with clinical trial patient selection.
By the numbers: Globally, the combined annual market potential ofthese programs is estimated to be approximately $11.0-13.0 billion,consisting of $5.0-6.0 billion for CNS cancers and $6.0-7.0 billion forsolid tumors.1.
The new collaboration with Bielefeld University (Germany) is focused on the development of AI-powered antibody-drug conjugates (ADCs), an exciting class of potent and highly targeted drug candidates.
Go deeper:
By the numbers: Globally, ADC drug programs are one of the fastest-growing drug development markets. In 2021, the ADC market was over$4.o billion and is projected to represent a global market potential of over$14 billion by 2027.
What’s next: Lantern anticipates using the AI ADC development module with other collaborators, both academic and commercial, to develop promising ADC candidates for launch into targeted clinical trials.
Lantern recently dosed the initial patients in the Harmonic™ trial and continues to dose and screen additional patients across its trial sites across the US.
The Harmonic™ trial has 5 trial sites across the US including Gabrail Cancer Center, Northwest Oncology, New York Cancer and Blood Specialists, Texas Oncology, and the Cancer and Blood Specialty Clinic -Los Alamitos CA. The activation of multiple additional trial sites in the US is anticipated in the coming quarters to bolster patient enrollment.
Go deeper: For more info on the Harmonic™ clinical trial check out the:
At the ASCO 2023 annual meeting, Lantern presented the development of advanced machine-learning (ML) modeling to accurately predict patient responses to Actuate Therapeutics’ drug candidate Elraglusib (9-ING-41).
Go deeper:
Development of a Machine Learning Model to Predict Patient Elraglusib Response with Genomic Input
What’s next:
The blood-brain-barrier (BBB) is a highly selective border that prevents 98% of drugs from entering brain tissues and is a major hurdle for biopharma companies developing neuro-oncology drugs.
To solve this problem, Lantern developed industry-leading AI algorithms that are capable of rapidly and accurately predicting any compound’s BBB permeability.
Lantern’s BBB permeability prediction AI algorithms were evaluated and scored as the top-4 best-performing algorithms in the BBB drug prediction challenge conducted by Therapeutics Data Commons (TDC), a coordinated initiative to evaluate AI capabilities across therapeutic modalities and stages of discovery.
Go deeper: Lantern’s industry-leading BBB prediction AI algorithms are:
What’s next for the BBB permeability prediction AI algorithms:
Q1 2023 earnings call replay and press release:
Lytham Partners Investor Conference 2023 fireside chat webinar with Panna Sharma, Lantern’s CEO and President:
RedChip Investor Group Call with Lantern with Panna Sharma:
